| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LCTX | Common Shares | Purchase | $7M | +6.73M | +19.27% | $1.04 | 41.7M | Feb 6, 2024 | Direct | F1, F2 |
| transaction | LCTX | Common Shares | Purchase | $0 | 0 | 0% | $0.00* | 41.7M | Feb 6, 2024 | See Footnote | F1 |
| holding | LCTX | Common Shares | 87.6K | Feb 6, 2024 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| F2 | On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share. |
| F3 | These securities are owned by Neal C. Bradsher in his personal capacity. |